6 天前 - … ), tafamidis significantly … treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Real-world evidence on survival in patients with ATTR-CM following tafamidis treatment …

9 天前 - … There are various classes of medications for the treatment of ATTR cardiac amyloidosis,
but tafamidis is the only medication approved by the Food and Drug Administration that …

14 天前 - … to 11% of hospitalized patients with heart failure with … transthyretin stabilization
using tafamidis or acoramidis to gene silencing using patisiran or inotersen to even gene therapy …

16 天前 - … to treat patients with transthyretin amyloidosis (ATTR). These include stabilizers (eg,
tafamidis, … pathway addressing the management of amyloid cardiomyopathy, routine use of …

17 天前 - … Genetic testing revealed no mutations in TTR-related genes. Therefore, the final …
the patient was treated with 80 mg of oral tafamidis per day. Three years after starting treatment…

20 天前 - … cardiac amyloidosis and to demonstrate changes in cardiac uptake of 99mTc-HMDP
after tafamidis treatment. … SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J …

26 天前 - … hazard of heart failure (HF) hospitalization or death compared to White patients
across … Despite equitable initiation of disease-specific treatment with tafamidis, Black patients …

26 天前 - … Among these patients, 9 remained untreated, while 2 underwent treatment initiation
with tafamidis. For image analysis, conventional axial images were reconstructed and 17 …

34 天前 - … Persistence was high with 78% of patients … tafamidis in this real-world Japanese
patient population. Adherence rates in this study were similar to those reported by the tafamidis …

40 天前 - … In 101 patients with wild‐type transthyretin amyloid cardiomyopathy receiving
tafamidis at our institution, change in cardiac biomarkers from baseline to 1 year after tafamidis …